 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...4243444546474849505152...208209» |
- | Journal: Molecular response of a patient with e19a2-positive chronic myeloid leukemia to flumatinib: a case report and literature review. (Pubmed Central) - Apr 1, 2025
Patients with the e19a2 transcript often show poor response to first-line treatment with imatinib, and no standard therapy has been established for this subtype...Following treatment discontinuation and prednisone therapy, the patient continued dasatinib (80?mg/d)...The patient was then switched to flumatinib (600?mg/d), achieving major molecular response (MMR) at 6?months and deep complete molecular response (MR4.5) at 24?months, with good tolerance. Flumatinib demonstrated excellent deep molecular response and good tolerability in e19a2-positive CML patients, suggesting that it may be one of the preferred treatment options for such patients.
- | Promacta (eltrombopag) / Novartis, Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Journal: Comparison of Hetrombopag and Eltrombopag Added to First-Line Immunosuppressive Therapy in Severe Aplastic Anemia. (Pubmed Central) - Mar 31, 2025
The addition of HPAG to standard IST in SAA patients showed similar response rates and response quality to that of EPAG. HPAG could be an alternative to EPAG for the first-line treatment of SAA patients.
- | recaticimab (SHR-1209) / Jiangsu Hengrui Pharma
New P4 trial: PISTIAS-2: PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis (clinicaltrials.gov) - Mar 31, 2025
P4, N=300, Not yet recruiting, Sponsor: Peking Union Medical College Hospital
- | Mekinist (trametinib) / Novartis, BeOne Medicines, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P1 trial: Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and Adolescents (clinicaltrials.gov) - Mar 31, 2025
P1, N=6, Enrolling by invitation, Sponsor: Second Affiliated Hospital of Wenzhou Medical University
- |||| retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
Trial completion date, Trial primary completion date: SHR-1701-III-307: A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer (clinicaltrials.gov) - Mar 30, 2025
P3, N=737, Active, not recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
HPAG could be an alternative to EPAG for the first-line treatment of SAA patients. Trial completion date: Jun 2025 --> Oct 2025 | Trial primary completion date: Mar 2025 --> May 2024
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Retrospective data, Journal: First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis. (Pubmed Central) - Mar 30, 2025
Pyrotinib-based combination therapy is a feasible first-line treatment for HER2-mutant NSCLC, demonstrating significant survival benefits and manageable toxicity. However, brain metastasis patients require enhanced comprehensive management.
- ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma
Ruzinurad for hyperuricemia associated with primary gout: a multicenter, randomized, double-blind, active-controlled, phase 3 study (Room 6.1) - Mar 30, 2025 - Abstract #EULAR2025EULAR_1860;
P3
However, brain metastasis patients require enhanced comprehensive management. The URAT1 inhibitor ruzinurad demonstrated superior sUA lowering effect over allopurinol, along with a well-tolerated safety profile, in patients with hyperuricemia associated with primary gout.
- ivarmacitinib (SHR0302) / Jiangsu Hengrui Pharma, Arcutis
Ivarmacitinib improves different dimensions of patient-reported outcomes in patients with active ankylosing spondylitis: a post-hoc analysis of a phase II/III trial (Poster Tour IV) - Mar 30, 2025 - Abstract #EULAR2025EULAR_1668;
P2/3
Ivarmacitinib significantly enhances multiple dimensions of PROs in active AS patients, supporting its utility in managing PROs in AS. Switching to Ivarmacitinib also provides substantial benefits, ensuring that patients who delay initiation of Ivarmacitinib also experience meaningful improvements in PROs.
- vunakizumab (SHR-1314) / Jiangsu Hengrui Pharma
Efficacy and safety of vunakizumab in active ankylosing spondylitis with and without prior TNF-a inhibitor exposure: a post-hoc analysis of a randomized, double-blind, phase 2/3 study (Poster Tour IV) - Mar 30, 2025 - Abstract #EULAR2025EULAR_1660;
P2/3
Vunakizumab showed efficacy and acceptable safety in patients with active AS, regardless of prior TNFi exposure. These findings warrant validation in future studies.
- vunakizumab (SHR-1314) / Jiangsu Hengrui Pharma
Vunakizumab Therapeutic Response in Ankylosing Spondylitis: Insights from BMI-Based Subgroup Analysis (Poster Area) - Mar 30, 2025 - Abstract #EULAR2025EULAR_1381;
P2/3
Vunakizumab 120 mg significantly improved AS symptoms across BMI categories, with consistent efficacy and rapid response observed in both subgroups. These results highlight its potential as a valuable treatment option for AS patients, regardless of BMI.
- ivarmacitinib (SHR0302) / Jiangsu Hengrui Pharma, Arcutis
Efficacy of Ivarmacitinib in patients with active ankylosing spondylitis stratified by baseline characteristics: a post-hoc analysis of a phase II/III trial (Poster Area) - Mar 30, 2025 - Abstract #EULAR2025EULAR_866;
P2/3
These results highlight its potential as a valuable treatment option for AS patients, regardless of BMI. Ivarmacitinib significantly improves treatment response in active AS across subgroups, especially in those with younger age, lower BMI, shorter disease duration, and without a history of biological/JAK inhibitors.
- ivarmacitinib (SHR0302) / Jiangsu Hengrui Pharma, Arcutis
Ivarmacitinib reduces the need for concomitant medication in moderate-to-severe rheumatoid arthritis patients: a post-hoc analysis from a phase III trial (Poster Area) - Mar 30, 2025 - Abstract #EULAR2025EULAR_424;
P3
Ivarmacitinib significantly improves treatment response in active AS across subgroups, especially in those with younger age, lower BMI, shorter disease duration, and without a history of biological/JAK inhibitors. Ivarmacitinib reduces the need for additional RA medications, thereby decreasing treatment burden.
- ivarmacitinib (SHR0302) / Jiangsu Hengrui Pharma, Arcutis
Effect of Ivarmacitinib on patient-reported outcomes in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: a post hoc analysis of a phase III trial (Poster Area) - Mar 30, 2025 - Abstract #EULAR2025EULAR_422;
P3
Ivarmacitinib reduces the need for additional RA medications, thereby decreasing treatment burden. Ivarmacitinib significantly and sustained improves patient-reported outcomes in patients with moderate-to-severe RA who have not responded well to csDMARDs.
- Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
Study on the Efficacy and Safety of Henagliflozin Combined with Continuous Subcutaneous Insulin Infusion in the Treatment of Type 2 Diabetes (Poster Hall (Hall F1); Board No 899) - Mar 29, 2025 - Abstract #ADA2025ADA_1698;
Ivarmacitinib significantly and sustained improves patient-reported outcomes in patients with moderate-to-severe RA who have not responded well to csDMARDs. Available on Friday, June 13, 2025 at 08:00am CDT.
- HRS9531 injection / Kailera Therapeutics
Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist (HRS9531), in Obese Adults without Diabetes (Poster Hall (Hall F1); Board No 853) - Mar 29, 2025 - Abstract #ADA2025ADA_1655;
Available on Friday, June 13, 2025 at 08:00am CDT. Available on Friday, June 13, 2025 at 08:00am CDT.
- HRS-7535 / Kailera Therapeutics
Efficacy and Safety of a Novel Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist (HRS-7535) in Type 2 Diabetes Mellitus Patients Inadequately Controlled by Metformin (Poster Hall (Hall F1); Board No 837) - Mar 29, 2025 - Abstract #ADA2025ADA_1639;
Available on Friday, June 13, 2025 at 08:00am CDT. Available on Friday, June 13, 2025 at 08:00am CDT.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Efficacy and saftey of neoadjuvant trastuzumab, pyrotinib and chemotherapy in HER2-positive breast cancer: A real-world study (Hall B0) - Mar 29, 2025 - Abstract #ESMOBC2025ESMO_BC_503;
P
Chemotherapy includes docetaxel, paclitaxel liposome, and carboplatin combined with docetaxel .Surgery was performed after the completion of study treatment. A dual HER2-targeted combination of pyrotinib and trastuzumab, along with chemotherapy further verified its effectiveness and safety in the real world.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Retrospective data, Review, Journal: PD-1 inhibitors improve the efficacy of transcatheter arterial chemoembolization combined with apatinib in advanced hepatocellular carcinoma: a meta-analysis and trial sequential analysis. (Pubmed Central) - Mar 29, 2025
Adding PD-1 inhibitors to TACE combined with apatinib significantly prolonged OS and PFS, particularly in patients without extrahepatic metastases. It also improved ORR and DCR in patients with HCC.
- || Review, Journal: CDK4/6 as a Therapeutic Target in HR+/HER2- Breast Cancer Cells-Current Treatment Status. (Pubmed Central) - Mar 28, 2025
Moreover, dalpiciclib is being investigated in HR+/HER2- BC treatment. This article will summarize clinical efficacy, recommendations, and differences in toxicity profile between palbociclib, ribociclib, and abemaciclib and will also discuss the possibility of using dalpiciclib in the treatment of breast cancer.
- || trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment open: SHR-A1811-105: Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer (clinicaltrials.gov) - Mar 28, 2025
P1, N=32, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
This article will summarize clinical efficacy, recommendations, and differences in toxicity profile between palbociclib, ribociclib, and abemaciclib and will also discuss the possibility of using dalpiciclib in the treatment of breast cancer. Not yet recruiting --> Recruiting
- || AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Efficacy and safety of radiotherapy versus transarterial chemoembolization in combination with lenvatinib and camrelizumab for hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multicenter study. (Pubmed Central) - Mar 27, 2025
Not yet recruiting --> Recruiting In combination with lenvatinib and camrelizumab, RT significantly improves the prognosis of HCC with IVC/RATT compared to TACE, with a comparable safety profile.
- ||||| SHR-A2102 / Jiangsu Hengrui Pharma
New P2 trial: A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors (clinicaltrials.gov) - Mar 26, 2025
P2, N=400, Not yet recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- | New P1 trial, IO biomarker: Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC (clinicaltrials.gov) - Mar 26, 2025
P1, N=80, Recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University
- | TheraCIM (nimotuzumab) / Daiichi Sankyo, Biocon, Biotech Pharma, HRS-4642 / Jiangsu Hengrui Pharma
Enrollment open: HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Mar 26, 2025
P1/2, N=10, Recruiting, Sponsor: West China Hospital
In combination with lenvatinib and camrelizumab, RT significantly improves the prognosis of HCC with IVC/RATT compared to TACE, with a comparable safety profile. Not yet recruiting --> Recruiting
- Sulanda (surufatinib) / Hutchmed
Efficacy and mechanism of surufatinib combination with PD-1 monoclonal antibody and chemotherapy for the treatment of pancreatic cancer with liver metastasis in animal models (Section 19; Poster Board No: 9) - Mar 25, 2025 - Abstract #AACR2025AACR_9159;
P1/2
LM could alter the efficacy of NASCA in KPC mice through improving immunosuppressive microenvironment. The heterogeneity of mIHC is limited in LM and PL, but patients with CD68+CD163- and FOXP3+ in the stroma may benefit more from NASCA regimen, which may contribute to developing precise immunotherapy strategies for PDAC patients with LM.
- zongertinib (BI 1810631) / Boehringer Ingelheim
Zongertinib demonstrates potent efficacy against cancer cells harboring HER2 non-tyrosine kinase domain mutations (Section 35; Poster Board No: 26) - Mar 25, 2025 - Abstract #AACR2025AACR_8999;
Consistent with our results obtained using Ba/F3 models, HCC4006 HER2 V659E cells were sensitive to HER2 inhibition with zongertinib. Our findings indicate that zongertinib demonstrates comparable or more potent inhibitory activity for HER2 non-TKD mutants (e.g TMD and JMD) as HER2 TKD mutations, providing a potential therapeutic option for patients with these HER2 non-TKD mutant cancers.
- AiTan (rivoceranib) / HLB Bio Group
Notch mutations in subjects with recurrent or metastatic adenoid cystic carcinoma treated with rivoceranib from study RM-202 (Section 31; Poster Board No: 8) - Mar 25, 2025 - Abstract #AACR2025AACR_5170;
Previously unreported pathogenic NOTCH1-4 mutations were identified in ACC tumor samples from the RM-202 phase II trial. High rates of NOTCH4 L16 mutations suggest a novel mechanism of Notch pathway activation in ACC and represents a potential therapeutic target in this rare disease.
- INV-6452 / Ionova Life Sci
Discovery of INV-6452, a CDK2/4 inhibitor for the treatment of HR-positive HER2-negative breast cancer resistant to current CDK4/6 therapy (Section 53; Poster Board No: 20) - Mar 25, 2025 - Abstract #AACR2025AACR_5009;
High rates of NOTCH4 L16 mutations suggest a novel mechanism of Notch pathway activation in ACC and represents a potential therapeutic target in this rare disease. Abstract is embargoed at this time.
- M9466 / EMD Serono
M9466 (HRS-1167): A highly potent and selective PARP1 inhibitor with DNA trapping activity, monotherapy antitumor activity and synergistic potential with DDR inhibitors and chemotherapies (Section 22; Poster Board No: 2) - Mar 25, 2025 - Abstract #AACR2025AACR_4377;
P1
Thus, M9466 has strong single agent synthetic lethal activity in HRD models and combinability with selected DDRis and chemotherapies. Based on these data, Phase I clinical trials are evaluating M9466-based combinations in patients with advanced solid tumors, and colorectal cancer (NCT06421935, NCT06509906).
- retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: A phase II trial (Section 28; Poster Board No: 28) - Mar 25, 2025 - Abstract #AACR2025AACR_2834;
P=N/A
SHR-1701 plus famitinib showed promising efficacy and manageable toxicity in advanced BTC and PDAC, providing proof-of-concept for targeting PD-L1, TGF-?, and angiogenesis pathways simultaneously. The I/M score may help select patients most likely to benefit from this regimen.
- trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
SHR-A1811, a HER2-directed antibody-drug conjugate (ADC), in advanced HER2-mutant non-small cell lung cancer (NSCLC): Updated phase 2 results from HORIZON-Lung (Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)) - Mar 25, 2025 - Abstract #AACR2025AACR_2098;
The I/M score may help select patients most likely to benefit from this regimen. Abstract is embargoed at this time.
- | Journal, HEOR, Cost-effectiveness: Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis. (Pubmed Central) - Mar 25, 2025
While all six PD-1 inhibitors demonstrated clinical benefits, pembrolizumab and serplulimab were less favourable from a cost-effectiveness standpoint. Sensitivity analysis confirmed that drug prices and utility values are significant determinants of cost-effectiveness.
- | New trial, IO biomarker: ICT-HCC: Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 25, 2025
P=N/A, N=300, Not yet recruiting, Sponsor: Nanjing Tianyinshan Hospital
- || SHR-A2102 / Jiangsu Hengrui Pharma
Enrollment closed, Enrollment change: SHR-A2102-I-102: Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 25, 2025
P1, N=395, Active, not recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Sensitivity analysis confirmed that drug prices and utility values are significant determinants of cost-effectiveness. Recruiting --> Active, not recruiting | N=200 --> 395
- || garetatug rezetecan (SHR-A1904) / EMD Serono
Enrollment closed, Trial completion date, Trial primary completion date: SHR-A1904-I-101: A Study of SHR-A1904 in Patients With Advanced Solid Cancer (clinicaltrials.gov) - Mar 25, 2025
P1, N=107, Active, not recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Recruiting --> Active, not recruiting | N=200 --> 395 Recruiting --> Active, not recruiting | Trial completion date: Jan 2024 --> Dec 2025 | Trial primary completion date: Oct 2023 --> Dec 2025
- GSK5784283 / GSK
Enrollment closed: Pharmacokinetics, Pharmacodynamics, Safety, and Preliminary Efficacy of Subcutaneous Injection of SHR-1905 in Adolescent Asthmatic Subjects - an Open-label, Single-dose Phase II Clinical Study (clinicaltrials.gov) - Mar 25, 2025
P2, N=9, Active, not recruiting, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Recruiting --> Active, not recruiting | Trial completion date: Jan 2024 --> Dec 2025 | Trial primary completion date: Oct 2023 --> Dec 2025 Recruiting --> Active, not recruiting
- |||| Trial completion date, Trial primary completion date: CCGLC-001: Combined HAIC, TKI/anti-VEGF and ICIs As Conversion Therapy for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 24, 2025
P=N/A, N=300, Recruiting, Sponsor: Ze-yang Ding, MD
Recruiting --> Active, not recruiting Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Apr 2024 --> Jun 2025
- Do Utility Scores Derived From Different Preference-Based Measurements Influence the Results of Cost-Effectiveness Analysis? () - Mar 24, 2025 - Abstract #ISPOR2025ISPOR_1579;
Compared to using the utilities measured by SF-6Dv2, using EQ-5D-5L results in a higher QALY and larger incremental QALY. This difference would further expand as the patient
- NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
Early Patient-Reported Satisfaction in Patients Initiated on Perfluorohexyloctane for Dry Eye Disease () - Mar 24, 2025 - Abstract #ISPOR2025ISPOR_985;
PFHO patients reported high satisfaction with their medication, with a majority refilling their prescription. Almost all PFHO patients had prior OTC eye drop usage for over 12 months, potentially identifying a subset of the patient population likely to benefit from the novel treatment.
- Socioeconomic Value of Targeted Therapies for HER2+ Breast Cancer in National Reimbursement Drug List of China () - Mar 24, 2025 - Abstract #ISPOR2025ISPOR_264;
Socioeconomic values of 7 targeted therapies in National Reimbursement Drug list (NRDL) from 2023 to 2032 were estimated, covering Trastuzumab, Pertuzumab, Ado-trastuzumab Emtansine , pertuzumab + trastuzumab + hyaluronidase-zzxf (Subcutaneous Injection) , Neratinib, Pyrotinib and Fam-trastuzumab Deruxtecan . Targeted therapies for HER2+ in breast cancer significantly improve patients
- |||||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment open, Platinum resistant: A Study of SHR-A1811 in Subjects With Ovarian Cancer (clinicaltrials.gov) - Mar 24, 2025
P3, N=300, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Targeted therapies for HER2+ in breast cancer significantly improve patients Not yet recruiting --> Recruiting
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Nerlynx (neratinib) / Puma
New trial: Probiotics for Prevention of Pyrotinib/Neratinib-Induced Diarrhea in Breast Cancer Patients (clinicaltrials.gov) - Mar 24, 2025
P=N/A, N=308, Not yet recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- ||| HR19042 / Jiangsu Hengrui Pharma
Trial completion, Trial completion date, Trial primary completion date: A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis. (clinicaltrials.gov) - Mar 24, 2025
P2, N=69, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Mar 2025
- AiRuiKa (camrelizumab) / HLB Bio Group
Observational data, Journal, Real-world evidence: Camrelizumab-based therapies for the treatment of advanced lung cancer: a prospective, open-label, multicenter, observational, real-world study. (Pubmed Central) - Mar 24, 2025
Camrelizumab-based therapies may serve as potential treatments for patients with advanced lung cancer. However, further studies with an extended follow-up duration are warranted.
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Apatinib regulates the glycolysis of vascular endothelial cells through PI3K/AKT/PFKFB3 pathway in hepatocellular carcinoma. (Pubmed Central) - Mar 24, 2025
However, further studies with an extended follow-up duration are warranted. Apatinib influences the glycolytic pathway in the VECs of HCC a through the PI3K/AKT/PFKFB3 signaling pathway.
- | ivarmacitinib (SHR0302) / Jiangsu Hengrui Pharma, Arcutis
Journal: SHR0302 Improves Treg/Th17 Imbalance in Patients with Systemic Lupus Erythematosus. (Pubmed Central) - Mar 24, 2025
In addition, frequency of Th17 cells were reduced by SHR0302. Our study shows that SHR0302 regulating the JAK1/STAT3 pathway can be a new treatment option for SLE.
- ||| AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Journal, Adverse events: Correlation Between Treatment-Related Adverse Events and Efficacy of Camrelizumab in Combination With Apatinib in Patients With Unresectable Hepatocellular Carcinoma. (Pubmed Central) - Mar 24, 2025
In this study, the occurrence of irAEs did not predict the efficacy of camrelizumab in combination with apatinib, likely due to the decreased incidence and delayed occurrence. On the other hand, apatinib-related hypertension was associated with improved treatment efficacy.
- ||| SHR-1906 / Jiangsu Hengrui Pharma
Trial completion, Enrollment change: Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - Mar 24, 2025
P2, N=30, Completed, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
On the other hand, apatinib-related hypertension was associated with improved treatment efficacy. Recruiting --> Completed | N=108 --> 30
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Journal: Long-term survival in a patient with ruptured advanced hepatocellular carcinoma treated with nutritional therapy combined with apatinib and camrelizumab: a case report. (Pubmed Central) - Mar 23, 2025
This case showcases a multimodal treatment strategy for patients with advanced HCC with high tumor burden and rupture complications, integrating individualized immuno-targeted therapy, interventional treatment, and nutritional management and providing a possible approach for achieving a long-term survival. This comprehensive treatment method may offer new insights into improving the prognosis of patients with advanced HCC.
- | AiTan (rivoceranib) / HLB Bio Group
Journal: A Glutathione-Responsive System with Prodrug and Sensitization Strategies for Targeted Therapy of Glioma. (Pubmed Central) - Mar 22, 2025
To overcome the limitations associated with chemotherapeutic agents, such as high toxicity and non-specific adverse effects, a novel nanoparticle system comprising cRGD-modified and glutathione (GSH)-responsive polymers, and PEG-ss-Dox and apatinib (AP) (PDOX-AP/cRGD-NPs) is developed...In the interim, PDOX-AP/cRGD-NPs demonstrate significant efficacy in suppressing both ectopic and orthotopic growth of GL-261 gliomas, as well as orthotopic LN-229 gliomas, thereby markedly extending the median survival duration. This study introduces a promising targeted co-delivery system for combination chemotherapy.